Sydney, Australia 13 March 2020 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the signing of a Product Supply Agreement with the Idaho State University Idaho Accelerator Center (IAC) for the production and commercial supply of copper-67 (Cu-67). Under the new agreement, IAC will supply Clarity…
BELOIT, Wis. and Sydney, Australia – February 11, 2020 – NorthStar Medical Technologies, LLC (NorthStar), a global innovator in the production and distribution of radioisotopes used for medical imaging, and Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, today announced the signing of a Letter of Intent for the commercial supply…
Sydney, Australia 30 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that interim-CEO, Dr Colin Biggin, has moved to Managing Director and CEO of the Company, to lead Clarity through the next stages of clinical development and commercialisation. Dr Biggin’s background in radiopharmaceutical development…
Sydney, Australia 23 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Dr Jennifer Rosenthal as Director of Quality and Regulatory Affairs. Jennifer has more than 20 years’ management experience in the biotechnology industry, serving in senior director and executive level roles…
Sydney, Australia 3 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response on its Investigational New Drug (IND) application that the study may proceed from the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic…
Sydney, Australia 11 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Orphan Drug Designation (ODD) request with the U.S. Food and Drug Administration (FDA) for 64Cu-SARTATE™, a diagnostic for the clinical management of neuroendocrine tumours (NETs). NETs are a…
Sydney, Australia 3 September 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic and therapy) trial with 64Cu-SARTATE™ and 67Cu-SARTATE™ in…
Sydney, Australia 30 July 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Robert Vickery as Chief Financial Officer. Robert is a transaction and change focused finance executive with over 30 years of experience and extensive involvement in life sciences and early stage…
Sydney, Australia 8 May 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has completed its anticipated capital raising of $10,000,005.50. This includes the previously announced strategic investment of $5,000,002.75 from GenesisCare, the largest private provider of cancer treatment in Australia and Europe, an…
Clarity Pharmaceuticals was featured in Idaho State University News. The Idaho State University Accelerator Center is Clarity’s partner for the production of Copper-67. The article discusses the developments in copper-67 production and the positive effects it has on the expansion of our clinical development program. Read the full article here: https://www.isu.edu/news/2019-spring/isu-idaho-accelerator-center-announces-record-production-of-form-of-medical-isotope-copper-67-that-will-be-used-in-cancer-clinical-trials.html/